CHICAGO -- An investigational viral immunotherapy (CAN-2409; aglatimagene besadenovec) combined with a prodrug improved disease-free survival (DFS) when added to standard curative-intent radiotherapy for newly diagnosed localized prostate cancer, a phase III trial showed.

Over a median follow-up of about 50 months, men randomized to CAN-2409 plus prodrug valacyclovir had a 30% reduction in the risk for disease recurrence or death versus placebo plus valacyclovir (HR 0.70, 95% CI 0.52-0.94, P =0.0155), reported Theodore DeWeese, MD, of Johns Hopkins University School of Medicine in Baltimore.

The investigational product also showed benefit in a number of secondary outcomes.

"Along with its very favorable toxicity profile, CAN-2409 I think offers a potential ... paradigm shift in how we

See Full Page